5EB-72172-92436
5 vaccinations
3 coded responses
44 check-ins
3 free-text entries
2 call cases
- Sex
- —
- Age at first dose
- 66+
- ZIP prefix
- 352 / AL
- Registered
- 2021-01-20
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-01-20
Registered in v-safe
-
2021-01-20
Dose 1 — Pfizer-BioNTech
- 2021-01-22
- 2021-01-23
- 2021-01-24
- 2021-01-25
- 2021-01-26
- 2021-01-27
- 2021-02-03
-
2021-02-10
Dose 2 — Pfizer-BioNTech
-
2021-02-10
Survey response — day 0, dose 2MedDRA: Unevaluable event — Feeling: Good · HeadacheFree text: Had 2nd dose just 2 hours ago.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-02-11
Health check-in — days 1–6 daily, dose 2Feeling: Good · Site: Pain · Headache, Fatigue or tirednessAdult check-in
- 2021-02-12
- 2021-02-13
- 2021-02-14
- 2021-02-15
- 2021-02-16
- 2021-02-17
- 2021-02-24
- 2021-03-03
- 2021-03-10
- 2021-03-17
- 2021-03-24
- 2021-05-12
- 2021-08-11
-
2021-09-23
Dose 3 — Pfizer-BioNTech
- 2021-09-30
- 2021-10-07
- 2021-10-14
- 2021-10-21
- 2021-10-28
- 2021-11-04
- 2021-12-23
-
2022-03-24
Survey response — 6 months, dose 3MedDRA: Office visit, Panniculitis, Pre-existing disease — Feeling: Good · Get care from a doctor or other healthcare professionalFree text: Symptoms: Diagnosed with lipodermatosclerosis in left lower leg above ankle. Had bilateral surgery for venous insufficiency in 2010 of which diagnosis probably related. · Healthcare visit (other): Visited dermatologist after referral from my internist. Both visits in person.MedDRA releases: 2024-11 · check-in free text available
-
2022-03-24
Report sent to call center — 6 months, dose 3Get care from a doctor or other healthcare professional1 call case(s)
- 2022-03-28
-
2022-04-29
Dose 4 — Pfizer-BioNTech
-
2022-05-04
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
- 2022-05-14
- 2022-05-22
- 2022-05-27
- 2022-06-03
- 2022-06-12
- 2022-07-29
-
2022-10-28
Survey response — 6 months, dose 4MedDRA: Arthralgia, COVID-19, Chills, Diarrhoea, Exposure to SARS-CoV-2, Fatigue, Headache, Rhinorrhoea, SARS-CoV-2 test positive — Feeling: Fair · Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Diagnosed with Covid-19 on October 26, 2022. Exposed Oct 18. Faint positive on at home test on Oct 24. Experienced chills, pain at arthritic points, headache, fatigue, loose bowels, runny nose.MedDRA releases: 2024-11 · check-in free text available
-
2022-10-28
Report sent to call center — 6 months, dose 4Be unable to do your normal daily activities · Get care from a doctor or other healthcare professionalTelehealth, virtual health, or email health consultation · 1 call case(s)
- 2022-10-31
- 2022-10-31
-
2022-10-31
Call successfulNot applicable – Participant does not believe symptoms are related to vaccine and does not wish to fill
-
2023-01-23
Dose 5 — Pfizer-BioNTech
- 2023-02-05
- 2023-02-06
- 2023-02-13
- 2023-02-20
- 2023-02-27
- 2023-03-06
- 2023-04-26
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-01-20 | Pfizer-BioNTech | |
| 2 | 2021-02-10 | Pfizer-BioNTech | |
| 3 | 2021-09-23 | Pfizer-BioNTech | No |
| 4 | 2022-04-29 | Pfizer-BioNTech | No |
| 5 | 2023-01-23 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 successful
Free text
Release 4 — day 0, dose 2
Systemic reaction (other): Had 2nd dose just 2 hours ago.
Release 11 — 6 months, dose 3
Symptoms: Diagnosed with lipodermatosclerosis in left lower leg above ankle. Had bilateral surgery for venous insufficiency in 2010 of which diagnosis probably related.
Healthcare visit (other): Visited dermatologist after referral from my internist. Both visits in person.
Release 12 — 6 months, dose 4
Symptoms: Diagnosed with Covid-19 on October 26, 2022. Exposed Oct 18. Faint positive on at home test on Oct 24. Experienced chills, pain at arthritic points, headache, fatigue, loose bowels, runny nose.
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Office visit | · | · | ✓ |
| SD | Arthralgia | · | · | ✓ |
| SD | Chills | · | · | ✓ |
| SD | COVID-19 | · | · | ✓ |
| SD | Diarrhoea | · | · | ✓ |
| SD | Exposure to SARS-CoV-2 | · | · | ✓ |
| SD | Fatigue | · | · | ✓ |
| SD | Headache | · | · | ✓ |
| SD | Panniculitis | · | · | ✓ |
| SD | Pre-existing disease | · | · | ✓ |
| SD | Rhinorrhoea | · | · | ✓ |
| SD | SARS-CoV-2 test positive | · | · | ✓ |
| SRO | Unevaluable event | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release